A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse

Article Transplantation

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Alberto Ortiz et al.

Summary: Diabetes, hypertension, and cardiovascular disease have been traditionally considered risk factors for severe COVID-19, but recent studies have found that renal disease, especially dialysis, organ transplantation, and CKD, play a significant role in the mortality risk associated with COVID-19.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

Add to Collection

Letter Surgery

Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients

Monica Miele et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Letter Medicine, General & Internal

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

William A. Werbel et al.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Nassim Kamar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

Arne Sattler et al.

Summary: The study analyzed immune responses in kidney transplant recipients after receiving the BNT162b2 vaccine, finding weaker antibody responses in transplant patients compared to healthy individuals and most hemodialysis patients. Additionally, spike-specific T cell responses were significantly reduced in transplant patients, indicating a need for revised vaccination strategies in immunosuppressed individuals.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse

Related references

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

Export Citation

Share Paper